Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cue Biopharma (CUE) Invested Capital (2017 - 2025)

Cue Biopharma's Invested Capital history spans 9 years, with the latest figure at $14.7 million for Q3 2025.

  • For Q3 2025, Invested Capital fell 44.23% year-over-year to $14.7 million; the TTM value through Sep 2025 reached $14.7 million, down 44.23%, while the annual FY2024 figure was $21.8 million, 46.86% down from the prior year.
  • Invested Capital for Q3 2025 was $14.7 million at Cue Biopharma, down from $20.6 million in the prior quarter.
  • Across five years, Invested Capital topped out at $73.7 million in Q4 2022 and bottomed at $10.0 million in Q1 2025.
  • The 5-year median for Invested Capital is $52.0 million (2023), against an average of $46.4 million.
  • The largest annual shift saw Invested Capital surged 54.01% in 2021 before it tumbled 69.87% in 2025.
  • A 5-year view of Invested Capital shows it stood at $65.5 million in 2021, then rose by 12.51% to $73.7 million in 2022, then tumbled by 44.24% to $41.1 million in 2023, then plummeted by 46.86% to $21.8 million in 2024, then crashed by 32.65% to $14.7 million in 2025.
  • Per Business Quant, the three most recent readings for CUE's Invested Capital are $14.7 million (Q3 2025), $20.6 million (Q2 2025), and $10.0 million (Q1 2025).